Yiqi Chutan recipe combined with chemotherapy for treatment of patients with advanced non-small cell lung cancer: short-term curative effect and impact on serum levels of IL-2 and TNF-α and immune function

doi:10.3877/cma.j.issn.1674-0785.2021.12.007

Abstract

Abstract:

Objective

To evaluate the short-term curative effect of Yiqi Chutan recipe combined with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and explore its impact on the serum levels of interleukin-2 (IL-2) and tumor necrosis factor-α (TNF-α) and immune function.

Methods

A total of 86 patients with advanced NSCLC treated at Nanjing Chest Hospital from January 2019 to January 2021 were selected and divided into either an observation group or a control group using the random number table method, with 43 cases in each group. Both groups were treated with chemotherapy, and the observation group was additionally treated with Yiqi Chutan recipe. The treatment course of the two groups was 21 days as one cycle, and the treatment lasted for two cycles. The short-term efficacy and improvement of quality of life were compared between the two groups. Lesions size, serum levels of IL-2 and TNF-α, the change of immune function, and the incidence of toxicity reaction were also compared.

Results

The total effective rate in the observation group was higher than that of the control group (79.07% vs 55.81%, P＜0.05). After treatment, the lesion size was significantly smaller than that before the treatment in both groups (P＜0.05), and the lesion size of the observation group was significantly smaller than that of the control group (P＜0.05). The rate of quality of life improvement of the observation group was significantly better than that of the control group (83.72% vs 60.47%, P＜0.05). After treatment, the level of serum IL-2 increased and the level of TNF-α decreased in both groups (P＜0.05); the changes in the levels of serum IL-2 and TNF-α in the observation group were more significantly than those of the control group (P＜0.05). After treatment, the CD₃⁺ cells, CD₄⁺ cells, and CD₄⁺/CD₈⁺ rate in the observation group were higher than those before treatment (P＜0.05 each) as well as those of the control group (P＜0.05 each). Compared with the control group, the incidence of liver and kidney abnormalities, bone marrow suppression, gastrointestinal reactions, leukopenia, and fatigue in the observation group decreased significantly (P＜0.05 each).

Conclusion

Yiqi Chutan recipe combined with chemotherapy has a good short-term curative effect in patients with advanced NSCLC, and can increase the level of IL-2 and decrease the level of TNF-α, and improve the immune function of patients.

Key words: Yiqi Chutan recipe, Chemotherapy, Non-small cell lung cancer, Short-term efficacy, Interleukin-2, Tumor necrosis factor-α, Immune function

Jiu Yang, Mei Hong, Zhiyuan Liu, Nuo Zhu. Yiqi Chutan recipe combined with chemotherapy for treatment of patients with advanced non-small cell lung cancer: short-term curative effect and impact on serum levels of IL-2 and TNF-α and immune function[J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(12): 948-953.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2021.12.007

https://zhlcyszz.cma-cmc.com.cn/EN/Y2021/V15/I12/948

Figures/Tables 7

组别	例数	性别（例）男性/女性	年龄（岁， $x ¯$ ±s）	体质量指数（kg/m²， $x ¯$ ±s）	Ⅲ/Ⅳ期（例）	病灶大小（cm， $x ¯$ ±s）	基础疾病（例）
组别	例数	性别（例）男性/女性	年龄（岁， $x ¯$ ±s）	体质量指数（kg/m²， $x ¯$ ±s）	Ⅲ/Ⅳ期（例）	病灶大小（cm， $x ¯$ ±s）	高血压	糖尿病	高血脂
观察组	43	27/16	60.54±6.81	22.54±1.87	23/20	5.79±1.02	7	6	4
对照组	43	26/17	60.83±7.09	22.73±1.91	25/18	5.98±1.20	9	4	2
t/χ²值		0.049	0.193	0.466	0.189	0.791	0.307	0.453	0.179
P值		0.825	0.847	0.642	0.664	0.431	0.580	0.501	0.672

组别	例数	性别（例）男性/女性	年龄（岁， $x ¯$ ±s）	体质量指数（kg/m²， $x ¯$ ±s）	Ⅲ/Ⅳ期（例）	病灶大小（cm， $x ¯$ ±s）	基础疾病（例）
组别	例数	性别（例）男性/女性	年龄（岁， $x ¯$ ±s）	体质量指数（kg/m²， $x ¯$ ±s）	Ⅲ/Ⅳ期（例）	病灶大小（cm， $x ¯$ ±s）	高血压	糖尿病	高血脂
观察组	43	27/16	60.54±6.81	22.54±1.87	23/20	5.79±1.02	7	6	4
对照组	43	26/17	60.83±7.09	22.73±1.91	25/18	5.98±1.20	9	4	2
t/χ²值		0.049	0.193	0.466	0.189	0.791	0.307	0.453	0.179
P值		0.825	0.847	0.642	0.664	0.431	0.580	0.501	0.672

组别	例数	CR	PR	SD	PD	有效率
观察组	43	5（11.63）	29（67.44）	7（16.28）	2（4.65）	34（79.07）
对照组	43	2（4.65）	22（51.16）	14（32.56）	5（11.63）	24（55.81）
χ²值						5.296
P值						0.021

组别	例数	治疗前	治疗后
观察组	43	5.79±1.02	2.13±0.34^a
对照组	43	5.98±1.20	3.08±0.62^a
t值		0.791	8.810
P值		0.431	＜0.001

组别	例数	提高	稳定	下降
观察组	43	36（83.72）	5（11.63）	2（4.65）
对照组	43	26（60.47）	12（27.91）	5（11.63）
χ²值		5.780	3.593	0.622
P值		0.016	0.058	0.430

组别	例数	IL-2（μg/L）		TNF-α（μg/L）
组别	例数	治疗前	治疗后	治疗前	治疗后
观察组	43	5.73±1.70	12.89±2.14^a	6.67±1.89	2.54±0.46^a
对照组	43	5.81±1.52	8.86±1.87^a	6.42±1.96	3.89±0.74^a
t值		0.230	9.299	0.602	10.160
P值		0.819	＜0.001	0.549	＜0.001

组别	例数	CD₃⁺ T细胞（%）		CD₄⁺ T细胞（%）		CD₄⁺ T细胞/CD₈⁺ T细胞（%）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	43	54.32±3.76	58.71±2.98^a	34.15±2.29	38.64±3.08^a	1.23±0.18	1.57±0.21^a
对照组	43	54.60±3.51	50.73±3.07^a	34.06±2.31	31.13±2.78^a	1.25±0.14	1.03±0.13^a
t值		0.357	12.231	0.181	11.869	0.575	14.337
P值		0.722	＜0.001	0.857	＜0.001	0.567	＜0.001

组别	例数	肝肾异常	骨髓抑制	胃肠道反应	白细胞减少	乏力
观察组	43	7（16.28）	5（11.63）	8（18.60）	3（6.98）	4（9.30）
对照组	43	16（37.21）	16（37.21）	17（39.53）	13（30.23）	15（34.88）
χ²值		4.808	7.623	4.568	7.679	8.174
P值		0.028	0.006	0.033	0.006	0.004

References 18

1	钟秀丽, 冯岗. 老年非小细胞肺癌化疗患者p53及VEGF水平与生存状况的相关性 [J]. 中国老年学杂志, 2020, 40(15): 3183-3186.
2	张美娟. 非小细胞肺癌患者发病危险因素的Logistic回归分析 [J]. 中国卫生统计, 2020, 37(3): 462-464.
3	Jang HJ, Lee HS, Ramos D, et al. Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors [J]. J Thorac Cardiovasc Surg, 2020, 159(4): 1598-1610.
4	李冲, 吴双. 含铂类化疗方案同步放化疗治疗局部晚期非小细胞肺癌的临床疗效评价 [J]. 临床内科杂志, 2019, 36(4): 275-276.
5	张洪涛, 赵凤德, 黄思宇, 等. 吉非替尼片治疗铂类方案化疗失败的中晚期非小细胞肺癌患者的临床研究 [J]. 中国临床药理学杂志, 2020, 36(15): 2219-2221.
6	曾维予, 田雪飞, 邓哲. 清金化瘀汤治疗急性放射性肺炎的疗效及对炎症因子水平的影响 [J]. 湖南中医杂志, 2019, 35(7): 8-11.
7	中华人民共和国卫生部. 原发性肺癌诊疗规范(2011年版) [M]. 北京: 中国标准出版社, 2011: 2.
8	中华人民共和国卫生部. 中药新药临床研究指导原则 [M]. 北京: 中国医药科技出版社, 1995: 219.
9	Fitzgerald K, Simone CB. Combining immunotherapy with radiation therapy in non-small cell lung cancer [J]. Thorac Surg Clin, 2020, 30(2): 221-239.
10	钟锐, 邬麟, 王伟, 等. 含铂化疗及其联合治疗在晚期非小细胞肺癌治疗中的研究进展 [J]. 肿瘤药学, 2019, 9(6): 839-844.
11	陆宽, 张博, 窦欣, 等. MSCT在含铂双药方案全身化疗治疗非小细胞肺癌的疗效评价中的应用价值 [J]. 肿瘤药学, 2018, 8(6): 955-959.
12	李冲, 吴双. 含铂类化疗方案同步放化疗治疗局部晚期非小细胞肺癌的临床疗效评价 [J]. 临床内科杂志, 2019, 36(4): 275-276.
13	王亚飞, 季也民, 赵娇阳. 益气养阴方辅助铂类为主联合化疗方案治疗气阴两虚型晚期非小细胞肺癌临床研究 [J]. 新中医, 2020, 52(16): 100-103.
14	李华, 郭丽, 憨镔, 等. 益气养阴化瘀方治疗肺癌术后复发和转移临床研究 [J]. 新中医, 2020, 52(4): 118-121.
15	宋振民, 李慧, 强亚杰, 等. 沙参麦冬汤加减联合GP化疗治疗晚期非小细胞肺癌疗效研究 [J]. 陕西中医, 2018, 39(4): 461-463.
16	扶志敏, 邝世晏, 李炽光, 等. 非小细胞肺癌血清中IL-2、IL-6、TNF-α和IFN-γ变化与生存率相关性研究 [J]. 中国现代医生, 2019, 57(11): 32-36.
17	李少昆, 安生花, 郭凤龙, 等. 肺癌患者血清TNF-α、IL-6与凝血功能的相关性研究 [J]. 实用癌症杂志, 2018, 33(11): 1773-1776.
18	郑和平, 黄梅, 蒲廷, 等. 加减沙参麦冬汤辅助治疗肺癌患者对免疫功能及不良反应的影响 [J]. 西部医学, 2020, 32(6): 896-899, 903.

[1]	Jie Shi, Yuntao Li, Haiyan Gao. Prognosis of node-positive luminal A breast cancer patients with neoadjuvant and adjuvant chemotherapy and influencing factors [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 353-361.
[2]	Minrong Ma, Cong Li, Qin Zhou. Current research status of treatment of cervical cancer [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 497-504.
[3]	Tingting Li, Heyu Wu, Yue Zhang, Kang Cheng, Xiaofang Zhang, Yachan Cheng. Study on the application of combined insulation strategy in laparoscopic anatomic hepatectomy in elderly patients [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 522-525.
[4]	Tao Chen, Hong Luo, JingJun Zhou. Risk factors of acute adverse reactions in elderly patients with esophageal cancer treated with radiotherapy alone and concurrent radiotherapy and chemotherapy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(04): 405-407.
[5]	Yujie Xu, Guodong Zhao. Advances and challenges in the treatment of advanced gastric cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(04): 451-455.
[6]	Mingjie Song, Qinglei Han, Jialong Li, Yingmei Shao. Current status of endoscopic ablation for advanced extrahepatic bile duct malignancies [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(03): 340-342.
[7]	Chenglu Huang, Fei Liao, Xianping Liu, Zhiqiang Wang. Relationship between overexpression of serum exosomal has_circ_0060937 and metastasis and poor prognosis of NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(04): 490-494.
[8]	Jialin Gao, Yajuan Cao. Anatomical laparoscopic right posterior lobectomy for isolated liver metastases after radical esophageal cancer resection [J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2023, 16(04): 239-242.
[9]	Chenrui Wu, Rui Liao, Qiang He. Hepatic arterial infusion chemotherapy combined immunotargeted therapy for multiple metastatic hepatocellular carcinoma in a multi-disciplinary treatment model: a case report [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 713-716.
[10]	Binkui Li. Conversion therapy for unresectable intrahepatic cholangiocarcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 511-516.
[11]	Hechun Tang, Shanping Ye, Dongning Liu, Weiquan Zhu, Zhixiang Huang, Taiyuan Li. A prospective randomized controlled study of the effect of natural orifice specimen extraction during robotic rectal radical resection on stress response and cellular immune function [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(04): 272-281.
[12]	Guangjun Zhong, Chunhua Liu, Wansen Zhu, Xiaolei Xu, Zhaojun Wang. Application of conventional MRI combined with different scanning sequences in preoperative staging diagnosis, chemotherapy efficacy and prognosis evaluation of gastric cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 378-382.
[13]	Jing Sheng, Yong Mei, Pei Xia, Xiaolin Wang. Clinical study of second-line treatment of advanced gastric cancer with ubenimex combined with irinotecan [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 317-321.
[14]	Qiuqiong Li, Jing Xue, Min Wang, Fen Chen, Meifang Xiao. Diagnostic value of serum and cerebrospinal fluid levels of NSE, SIL-2R, and TNF-α in children with viral meningitis and bacterial meningitis [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(03): 303-307.
[15]	Xiaowu Zhang, Pengfei Tian, Wei Li, Qing Peng, Jingui Li, Deshen Li, Xiao Li. Comparison of subcutaneous central venous port via jugular and subclavian access: a retrospective study [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2023, 11(04): 301-304.

Please choose a citation manager

Content to export